u/rosa_sandvik

Not convinced by that integration. Dropping the baseline there absorbs part of the shoulder into the main peak.

That delay was at clearance, not with the carrier. The lane table separates them for exactly this reason.

integration decisions move the number more than the sample does

Australia and New Zealand are separate systems and get conflated weekly

Not convinced by four data points. That is not a lane yet, it is an anecdote with a route attached.

Someone posted US advice in an Australian thread and it took four replies to untangle it. Say your country.

Yes — system suitability first. Without it the number is an assertion about the instrument, not the sample.

the Medsafe position in New Zealand is its own thing entirely

research-use-only labelling is not a customs category

Yes — write the concentration in the log as well as on the vial. Belt and braces and it costs nothing.

Ran a blank after a high-concentration injection and found the carryover I had been calling an impurity.

Agreed. And the corollary is that the method line on a certificate is not decoration, it is the number’s provenance.

That is area percent, not mass percent. The trace cannot give you the second one.

origin, destination, carrier, month — post all four or the report is noise

Carryover from a previous high-concentration injection looks exactly like a small impurity.

peak_area_pete is right — the integration choice is a decision and it should be stated alongside the result.

Did you run a blank between injections?

a quoted lead time you can hold them to is worth more than a fast one you cannot

How long have you been logging?

Is the concentration recorded anywhere in the log?

Yes — system suitability first. Without it the number is an assertion about the instrument, not the sample.

Push back: comparing a July transit with a February one on the same lane is not a comparison.

do not import US advice into an Australian thread

Correction: those two entries are 21 weeks apart, not consecutive, which changes how the middle of that series reads.

Are the missed weeks in there as blanks or dropped entirely?

A log is a record of what you did.

amara_dziedzic is right about blanks. Silent gaps make the series lie.

compounded supply arrangements changed and the threads have not caught up

Agreed — the database rather than the coverage, every time.

report the method or do not report the number

Cosigning on paperwork. The boring documents are the ones that matter when a process starts.

Push back: comparing a July transit with a February one on the same lane is not a comparison.

report the method or do not report the number

the boring logs are the useful ones

Small fix — 214nm, not 210. It matters for the comparison you are making with the other run.

The compounded arrangements changed while I was mid-thread and I was arguing from a superseded position.

Mass spectrometry answers identity.

kofi_ferreira is right — the integration choice is a decision and it should be stated alongside the result.

Cosigning on missed weeks. Leaving them blank makes the whole series misleading.

Disagree. Inter-lab spread of a point or two on this assay is ordinary and calling it a discrepancy misleads people.

Same view — reporting the gradient is what makes a result checkable rather than merely stated.

Someone posted US advice in an Australian thread and it took four replies to untangle it. Say your country.

a lane with four reports is not yet a lane

ask the pharmacy to check the wholesaler rather than guessing

Not convinced by four data points.

Adding the field everyone forgets — the month. Without it the report is not comparable to anything.